Belgium-based Mithra has signed a binding Head of Terms agreement with biopharmaceutical company Libbs for an exclusive licence to commercialise its new combined oral contraceptive (COC) product, Estelle, in Brazil.

Both companies are dedicated to women’s health.

Mithra’s Estelle is a new oral contraceptive product candidate that comprises 15mg of Estetrol (E4), its unique native estrogen and 3mg of Drospirenone (DRSP).

Under the deal, Mithra is eligible to receive an upfront milestone payment of €20m, half of which will be non-refundable, with the other half depending on certain development and regulatory outcomes.

In addition, it will receive guaranteed annual recurring revenues depending on minimum annual quantities (MAQ) and binding forecasts, and 40% royalties on net sales above these levels.

“Libbs’ confidence in the potential of Estelle to offer a convenient and safer combined oral contraceptive to Brazilian women is reflected in the strong deal terms, and we are very much looking forward to working with them.”

Mithra CEO François Fornieri said: “Libbs’ confidence in the potential of Estelle to offer a convenient and safer combined oral contraceptive to Brazilian women is reflected in the strong deal terms, and we are very much looking forward to working with them.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Estetrol-based COC product candidate is currently undergoing pivotal, open-label, single-arm Phase III trials, E4 Freedom, in the US, Canada, Europe and Russia.

Top-line results from the trials in the US and Canada are expected in the third quarter of next year, while study results from Europe and Russia are expected in the first quarter of 2019.

The two companies will work in collaboration on the regulatory submissions and other steps required for approval and launch of the product in Brazil.

In July last year, the company received approval from the US Food and Drug Administration (FDA) for the Phase III clinical trials of Estelle.